CEO Awarded $18M Performance Equity to Drive 54-146% Stock Price Growth by 2029
Summary
Alnylam Pharmaceuticals granted its CEO, Dr. Yvonne Greenstreet, a special performance-based equity award valued at $18 million, contingent on achieving significant stock price appreciation by 2029.
Key Events
-
CEO Performance Award
Alnylam's Board granted CEO Dr. Yvonne Greenstreet a special equity award with a target value of $18.0 million, based on the closing price of $325.07 on the grant date of March 2, 2026.
-
Performance-Based Vesting
The award is fully performance-based, requiring the stock price to achieve thresholds between $500 and $800 by December 31, 2029. This represents a 54% to 146% increase from the grant date price, with the award forfeited if the stock does not reach $500.
-
Strategic Retention
The award aims to retain and incentivize Dr. Greenstreet, who led the company to its first annual net income in 2025, through its next phase of growth under the "Alnylam 2030" goals.
Analysis
This filing details a substantial performance-based equity award for CEO Dr. Yvonne Greenstreet, designed to incentivize her leadership through the company's "Alnylam 2030" growth phase. The award, with a target value of $18 million, is entirely contingent on the stock price reaching aggressive targets, requiring a 54% to 146% increase from the grant date price by December 2029. This strategic compensation aligns the CEO's long-term interests directly with significant shareholder value creation, following a period where she successfully led the company to its first annual net income in 2025. Investors should view this as a strong signal of confidence in the company's future trajectory and a commitment to retaining key leadership.
At the time of this filing, ALNY was trading at $330.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.4B. The 52-week trading range was $205.87 to $495.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.